Sabine Pellett1, William H Tepp2, Eric A Johnson3, Dorothea Sesardic4. 1. Department of Bacteriology, University of Wisconsin, 1550 Linden Dr., Madison, WI 53706, United States. Electronic address: Sabine.pellett@wisc.edu. 2. Department of Bacteriology, University of Wisconsin, 1550 Linden Dr., Madison, WI 53706, United States. Electronic address: whtepp@wisc.edu. 3. Department of Bacteriology, University of Wisconsin, 1550 Linden Dr., Madison, WI 53706, United States. Electronic address: eric.johnson@wisc.edu. 4. Division of Bacteriology, National Institute for Biological Standards and Control (NIBSC), A centre of Medicines and Healthcare products Regulatory Agency; Hertfordshire EN6 3QG, UK. Electronic address: Thea.Sesardic@nibsc.org.
Abstract
INTRODUCTION: Botulinum neurotoxins (BoNTs), the causative agents of botulism, are widely used as powerful bio-pharmaceuticals to treat neuro-muscular disorders. Due to the high potency and potential lethality of BoNTs, careful monitoring of the biologic activity of BoNT-based pharmaceuticals is required to ensure safe usage. For decades, the only approved method for potency determination of pharmaceutical BoNTs was the mouse bioassay (MBA), but in recent years improvements in cell-assay technologies have enabled MBA replacement by cell-based assays for specific product evaluations. This project details a method for quantitative and sensitive detection of biologic activity of BoNT/A1 in human induced pluripotent stem cell (hiPSC) derived neurons using an ELISA as a method to determine SNAP-25 cleavage by BoNT/A1 following toxin exposure. METHODS: HiPSC derived neurons from two different sources were exposed to serial dilutions of BoNT/A1, and quantitative detection of toxin activity was evaluated and optimized in cell lysates using ELISA to detect cleaved SNAP-25. RESULTS: The results from this study indicate that an ELISA using ultra TMB as a substrate quantitatively detects cleaved SNAP-25 in cell lysates of BoNT/A1 exposed hiPSC-derived neuronal cells with similar or greater sensitivity as Western blot (EC50~0.3U/well). DISCUSSION: This study demonstrates a human specific and sensitive cell-based detection platform of BoNT/A1 activity using ELISA as an endpoint for quantitative detection of the SNAP-25 cleavage product. This assay is applicable to moderate to high-throughput formats and importantly employs non-cancerous human-specific neuronal cells for potency evaluation of a bio-pharmaceutical for human use.
INTRODUCTION: Botulinum neurotoxins (BoNTs), the causative agents of botulism, are widely used as powerful bio-pharmaceuticals to treat neuro-muscular disorders. Due to the high potency and potential lethality of BoNTs, careful monitoring of the biologic activity of BoNT-based pharmaceuticals is required to ensure safe usage. For decades, the only approved method for potency determination of pharmaceutical BoNTs was the mouse bioassay (MBA), but in recent years improvements in cell-assay technologies have enabled MBA replacement by cell-based assays for specific product evaluations. This project details a method for quantitative and sensitive detection of biologic activity of BoNT/A1 in human induced pluripotent stem cell (hiPSC) derived neurons using an ELISA as a method to determine SNAP-25 cleavage by BoNT/A1 following toxin exposure. METHODS: HiPSC derived neurons from two different sources were exposed to serial dilutions of BoNT/A1, and quantitative detection of toxin activity was evaluated and optimized in cell lysates using ELISA to detect cleaved SNAP-25. RESULTS: The results from this study indicate that an ELISA using ultra TMB as a substrate quantitatively detects cleaved SNAP-25 in cell lysates of BoNT/A1 exposed hiPSC-derived neuronal cells with similar or greater sensitivity as Western blot (EC50~0.3U/well). DISCUSSION: This study demonstrates a human specific and sensitive cell-based detection platform of BoNT/A1 activity using ELISA as an endpoint for quantitative detection of the SNAP-25 cleavage product. This assay is applicable to moderate to high-throughput formats and importantly employs non-cancerous human-specific neuronal cells for potency evaluation of a bio-pharmaceutical for human use.
Authors: Sarah Adler; Gerd Bicker; Hans Bigalke; Christopher Bishop; Jörg Blümel; Dirk Dressler; Joan Fitzgerald; Frank Gessler; Heide Heuschen; Birgit Kegel; Andreas Luch; Catherine Milne; Andrew Pickett; Heidemarie Ratsch; Irmela Ruhdel; Dorothea Sesardic; Martin Stephens; Gerhard Stiens; Peter D Thornton; René Thürmer; Martin Vey; Horst Spielmann; Barbara Grune; Manfred Liebsch Journal: Altern Lab Anim Date: 2010-08 Impact factor: 1.303
Authors: Regina C M Whitemarsh; William H Tepp; Marite Bradshaw; Guangyun Lin; Christina L Pier; Jacob M Scherf; Eric A Johnson; Sabine Pellett Journal: Infect Immun Date: 2013-08-05 Impact factor: 3.441
Authors: Kyle S Hubbard; Ian M Gut; Megan E Lyman; Kaylie M Tuznik; Mariano T Mesngon; Patrick M McNutt Journal: BMC Neurosci Date: 2012-10-24 Impact factor: 3.288
Authors: Ester Fernández-Salas; Joanne Wang; Yanira Molina; Jeremy B Nelson; Birgitte P S Jacky; K Roger Aoki Journal: PLoS One Date: 2012-11-21 Impact factor: 3.240
Authors: Andrea Pathe-Neuschäfer-Rube; Frank Neuschäfer-Rube; Gerald Haas; Nina Langoth-Fehringer; Gerhard Paul Püschel Journal: Toxins (Basel) Date: 2018-09-05 Impact factor: 4.546